微波子宫内膜去除术与子宫切除术治疗异常子宫出血的疗效比较

目的 比较微波子宫内膜去除术(MEA)和子宫切除术(AH)治疗异常子宫出血的疗效.方法 将异常子宫出血80例分为MEA组和AH组各40例,比较两组临床疗效、手术时间、术中出血及手术前后白细胞变化. 结果 MEA和AH治疗异常子宫出血的有效率无显著差异(39/40 vs 40/40,χ2=0.000,P=1.000).MEA手术时间短[(4.8±1.2)min vs(102.5±34.6)min,t=17.848,P=0.000];术中出血少[0 ml vs(138.3±40.6)ml,t=21.544,P=0.000]. 结论 MEA是一种治疗异常子宫出血有效且微创的手术.     

Performance and comparison of the Cockcroft-Gault and simplified Modification of Diet in Renal Disease formulae in estimating glomerular filtration rate in a Chinese Type 2 diabetic population.

AIMS: Our aim was to assess performances of the Cockcroft-Gault and simplified Modification of Diet in Renal Disease (MDRD) formulae in estimating glomerular filtration rate (GFR) in Chinese diabetic populations and their association with vascular risks. METHODS: A total of 1009 patients with Type 2 diabetes were categorized into low estimated GFR groups (GFR < 60 ml/min/1.73 m(2)) and control groups by the two equations. The performances of these formulae were assessed at different stages of kidney function. Carotid artery intima-media thickness (IMT) and the prevalence of diabetic retinopathy or albuminuria were compared among the groups. The ability of these formulae to identify established vascular risk markers using sensitivity, specificity, positive and negative predictive values were also compared. RESULTS: The prevalence of low estimated GFR was 32.7% with the Cockcroft-Gault formula and 5.2% with the MDRD formula, respectively. In low estimated GFR subjects by the MDRD formula, IMT was significantly thicker than those by the Cockcroft-Gault formula (1.2 mm vs. 1.0 mm; P < 0.05), with a higher prevalence of albuminuria (78.4 vs. 52.8%, P < 0.05) and diabetic retinopathy (46.5 vs. 30.5%; P < 0.05). The Cockcroft-Gault formula gave a specificity of 71.7% and a sensitivity of 37.0%, and the MDRD formula gave a specificity of 96.6% and a sensitivity of 7.9% in estimating low GFR relevant for established vascular risks. CONCLUSIONS: These formulae performed differently in Chinese diabetic populations. The simplified MDRD formula is minimally superior to the Cockcroft-Gault formula for its high specificity and positive predictive values in estimating low GFR relevant for vascular risks.     

“黄风湿”系列疗法——火针封闭治疗痛风石的疗效观察

痛风是一种由嘌呤代谢紊乱所致的疾病,日久不愈、反复发作则逐渐形成痛风石沉积。常规治疗对痛风石效果不明显。黄再军医院采用火针封闭疗法治疗痛风石36例,经临床观察治愈率为69.4%,显效率为25.0%,有效率为5.6%,总有效率达100%。     

乳腺非典型增生病与血管生成关系的实验研究

目的：建立乳腺非典型增生病动物模型，探讨非典型增生与血管生成的关系。方法：采用灌服二甲基苯蒽＋颈部枷具方法复制大鼠肝郁血瘀型乳腺非典型增生动物模型，并给予中药乳复汤治疗。常规染色观察大鼠乳腺组织病理组织形态．免疫组化方法检测MVD、VEGF和bFGF的表达。结果：病证模型组乳腺非典型增生率90％．较单纯造模组高．P=0．0415；中药乳复汤治疗组非典型增生率较病证模型组低．P=0．0459；随着一般增生到非典型增生程度加重，MVD计数增多，VEGF、bFGF的表达升高，P〈0．05。结论：病证结合造模更适合中医动物实验要求，中药乳复汤具有抑制血管生成作用。     

放疗科病人医院感染原因分析与控制

医院感染是指病人在入院时不存在,也不处于潜伏期,而是在医院内发生的感染,也包括在医院里获得治疗,出院后发病的病人感染[1].癌症病人是一个特殊的群体,是医院感染的易感和高危人群,由于疾病本身引起消瘦无力、营养不良、甚至恶病质,免疫力低下、再加上接受放射线治疗后引起骨髓功能抑制、消化道功能障碍、皮肤反应及其他副反应等危险因素,医院感染发生率高,因此放疗科的医院感染控制是非常重要的工作.本文通过对我院放疗科病房2003年8月-2004年4月住院病人137例中发生医院感染病例12例进行分析,总结出一些控制医院感染的方法,现将其介绍如下.……     

继发性外部性脑积水的CT诊断及随访观察

目的探讨继发性外部性脑积水的CT特征及随访观察的价值.方法回顾性分析了36例有明确病因的继发性外部性脑积水的CT特征及随访结果.结果双侧额或额顶部蛛网膜下腔对称性增宽者36例(100%),双侧裂池增宽者36例(100%),额顶部脑沟增宽加深者31例(86.11%),前纵裂池增宽者36例(100%),脑基底池扩大者21例(58.33%),脑室轻度扩大者7例(19.44%).复查10例患儿其中8例外部性脑积水及临床症状消失,智力良好.其余2例均伴外伤史,其中一例复查出现脑萎缩征象,另一例出现脑积水征象.结论C检查及随访观察对于继发性外部性脑积水的诊断、鉴别诊断及指导临床治疗具有重要的价值.     

Molecular determinants of cetuximab efficacy.

PURPOSE: To investigate whether mRNA expression levels of cyclin D1 (CCND1), cyclooxygenase 2 (Cox-2), epidermal growth factor receptor (EGFR), interleukin 8 (IL-8), and vascular endothelial growth factor (VEGF), all members of the EGFR signaling pathway, are associated with clinical outcome in patients with EGFR-expressing metastatic colorectal cancer (CRC) treated with cetuximab. PATIENTS AND METHODS: Thirty-nine patients with metastatic CRC, refractory to both irinotecan and oxaliplatin, were enrolled on IMCL-0144 and treated with single-agent cetuximab. The intratumoral mRNA levels of CCND1, Cox-2, EGFR, IL-8, and VEGF were assessed from paraffin-embedded tissue samples using laser-capture microdissection and quantitative real-time polymerase chain reaction. RESULTS: There were 21 women and 18 men with a median age of 64 years (range, 35 to 83 years). Higher gene expression levels of VEGF were associated with resistance to cetuximab (P = .038; Kruskal-Wallis test). The combination of low gene expression levels of Cox-2, EGFR, and IL-8 was significantly associated with overall survival (13.5 v 2.3 months; P = .028; log-rank test). Both findings were independent of skin toxicity that was itself significantly correlated to survival. Patients with a lower mRNA amount of EGFR had a longer overall survival compared with patients that had a higher mRNA amount (7.3 v 2.2 months; P = .09; log-rank test). Patients with lower expression of Cox-2 had a significantly higher rate of grade 2 to 3 skin reactions under cetuximab treatment. CONCLUSION: This pilot study suggests that gene expression levels of Cox-2, EGFR, IL-8, and VEGF in patients with metastatic CRC may be useful markers of clinical outcome in single-agent cetuximab treatment.     

Recent Advances in Structure-Based Virtual Screening of G-Protein Coupled Receptors

In addition to the rhodopsin crystal structure, high-resolution crystal structures of ligand-mediated G-protein-coupled receptors (GPCRs) have recently become available, and these have become attractive templates for developing homology models of several GPCRs of therapeutic interest. These crystal structures and the homology models derived from them have provided significant insights into ligand–receptor interactions. Moreover, several studies have demonstrated that the structural models are indeed suitable for virtual screening of compound databases to identify new ligands for various GPCRs. Recent examples of such virtual screening against GPCRs are discussed in this review.     

Characterization of bortezomib-adapted I-45 mesothelioma cells

Background  

Bortezomib, a proteasome-specific inhibitor, has emerged as a promising cancer therapeutic agent. However, development of resistance to bortezomib may pose a challenge to effective anticancer therapy. Therefore, characterization of cellular mechanisms involved in bortezomib resistance and development of effective strategies to overcome this resistance represent important steps in the advancement of bortezomib-mediated cancer therapy.